Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 10/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4147730 | 1.00 | P2RX7 (0.39) | P2RX7KMT2ACNR1CNR2ALDH1A1 | |
| SCHEMBL4142225 | 0.89 | P2RX7 (0.51) | P2RX7 | |
| SCHEMBL13243904 | 0.88 | P2RX7 (0.47) | P2RX7KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL13243903 | 0.88 | P2RX7 (0.47) | P2RX7KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL14135163 | 0.85 | P2RX7 (0.35) | P2RX7KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL4995800 | 0.84 | P2RX7 (0.37) | P2RX7KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL4140616 | 0.83 | LMNA (0.51) | P2RX7KMT2ACNR2ALDH1A1LMNA | |
| SCHEMBL5608843 | 0.82 | ALDH1A1 (0.42) | P2RX7KMT2ACNR2ALDH1A1LMNA | |
| SCHEMBL4135226 | 0.80 | LMNA (0.33) | P2RX7KMT2ACNR1CNR2ALDH1A1 | |
| SCHEMBL4137906 | 0.79 | ALDH1A1 (0.45) | P2RX7KMT2AALDH1A1LMNAEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170838-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. | 2009-07-02 | — | — | US | claimed |
| US-7402596-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2008-07-22 | — | — | US | claimed |
| US-20070197565-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. | 2007-08-23 | — | — | US | claimed |
| US-20090170838-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. | 2009-07-02 | — | — | US | disclosed |
| US-20090170838-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. | 2009-07-02 | — | — | US | disclosed |
| US-7402596-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2008-07-22 | — | — | US | disclosed |
| US-7402596-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2008-07-22 | — | — | US | disclosed |
| US-20070197565-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197565-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197565-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | P2RX7, P2RX3, P2RX2 | P2RX7 1/4885KMT2A 4614/4885CNR1 49/4885 |
| US-20090170838-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | P2RX7, P2RX3, P2RX2 | P2RX7 1/4885KMT2A 4614/4885CNR1 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.